Home Search
Psychiatric medications - search results
If you're not happy with the results, please do another search
Increased use of mental health drugs in patients with heart disease
According to a new study, nearly one in five patients with heart disease use mental health drugs, leading to almost a doubled risk of premature deaths with the condition.
Who will staff the psychedelic resurgence?
Who will staff the psychedelic resurgence? Erika Dyck, Professor and Canada Research Chair in History of Health & Social Justice from the University of Saskatchewan, provides an intriguing answer to this question.
Closing the innovation gap: Advancing psychedelic therapy and medicines in EU mental health care
Despite the growing burden of mental health problems, there remains a significant unmet medical need. Tadeusz Hawrot, Founder and Executive Director at Parea tells us why new treatments are urgently needed and how psychedelic therapy and medicines can help
Treatments for ADHD: Can neurotherapies help treat children and adults?
Professor Katya Rubia from the Institute of Psychiatry, Psychology, and Neurosciences at King’s College London discusses the potential of non-invasive brain therapies, including neurofeedback, as treatments for ADHD.
Medicinal cannabis: The future of chronic pain treatment?
Alberto Sainz Cort to discuss the prevalence of chronic pain and opioid use in the United States, as well as medical cannabis as a potential treatment for pain.
Biomedical research and innovation, including autism
Open Access Government provides a short introduction to biomedical research and innovation in the UK, including autism.
Psychedelic therapies are returning to psychiatry
Professor Erika Dyck, Canada Research Chair in History of Health & Social Justice at the University of Saskatchewan, looks to psychedelic therapies outside the pharmaceutical industry to aid mental illness.
Stolen Lives: The Reality of Living with Long Covid
Long Covid is affecting an estimated two million people in the UK; however, both the general population and the UK government have continued to overlook its impacts. This eBook sheds light on the life-changing condition.
Latinx & dementia: The challenge of behavioural symptoms
Dr Lynn Woods, Professor in the Department of Doctoral Programs, School of Nursing, Azusa Pacific University, provides further analysis of Latinx developing dementia, including systems of healing & the challenge of behavioural symptoms.
Dementia & Behavioural Symptoms of Dementia: Risk for the Latinx population
Dr Lynn Woods, Professor in the Department of Doctoral Programs, School of Nursing, Azusa Pacific University, explores behavioural symptoms of dementia in the Latinx population.
Driving the epilepsy field ahead with new research benchmarks
The National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), drives the epilepsy field ahead with new research benchmarks, Vicky Whittemore, PhD, Program Director reveals.
Vascular therapies for mental health disorders
Here, Dr Anju Vasudevan, discusses two distinct vascular therapies in the prenatal, postnatal, and adult brain to combat mental illness.
Researchers given £2.3m to investigate the neurological impacts of COVID-19
Researchers from the University of Liverpool and King’s College London have received a £2.3 million fund from UK Research and Innovation (UKRI) to investigate the neurological impacts of COVID-19.
Mental health care and the pharmaceutical industry
Marcin Rodzinka, Project Coordinator at Mental Health Europe explains how transparency between the pharma industry and health professionals can influence the quality of mental health care in Europe today
Sources of funding in the development of therapies for Huntington’s disease
Leora Fox, Jennifer Simpson and George Yohrling from the Huntington’s Disease Society of America explore the sources of funding in the development of therapies for Huntington’s disease (HD).
Environmental chemicals: factors for neurodevelopmental disorders?
Pamela Lein, University of California, looks at whether environmental chemicals influence individual risk for the diagnosis of neurodevelopmental disorders
Huntington’s disease: Understanding the impact
Jennifer Simpson of the Huntington’s disease Society of America highlights the disease and how there is still a long way to go before it can be truly understood